Biologic Therapy and Malignancy Risk in Psoriasis: A Retrospective Cohort Study.

ABSTRACT: The long-term impact of biologic therapy on malignancy risk in patients with psoriasis remains unclear. Given the chronic nature of psoriasis and the increasing use of biologics, understanding their long-term safety profile is crucial. This study aimed to compare the incidence of malignancy between patients receiving continuous biologic therapy and those treated with topical monotherapy. We retrospectively analyzed 446 patients with psoriasis treated at a single center between May 2010 and March 2023 (biologic therapy: n = 226; topical monotherapy: n = 220). Malignancy incidence was estimated using the Kaplan-Meier method. Multivariable Cox proportional hazards regression with propensity score adjustment was employed to control for confounding variables. Subgroup analysis was performed wit

SUBMITTER: Takamura S 

PROVIDER: S-EPMC12698904 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature